TITLE

Predictors of the location of multiple sclerosis relapse

AUTHOR(S)
Deen, S.; Bacchetti, P.; High, A.; Waubant, E.
PUB. DATE
October 2008
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Oct2008, Vol. 79 Issue 10, p1190
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: While clinical relapses are the defining feature of relapsing-remitting multiple sclerosis (RAMS), their characteristics vary widely from patient to patient. This study sought to identify predictors of MS relapse location. Based on the current literature, two potential predictors were identified: treatment with interferon β (IFNB) and location of previous relapse. Methods: Patients with RRMS were identified from the UCSF MS Center database who underwent at least 3 months of treatment with IFNB or glatiramer acetate (GA). The relapse immediately preceding the initiation of treatment (pretreatment relapse) and the first relapse occurring after the initiation of treatment (on-treatment relapse) were coded as affecting the spinal cord (SC), optic nerve (ON), brainstem/cerebellum (BC) or cerebrum. Logistic regression was performed to identify independent predictors of on-treatment relapse location. Results: The 134 IFNB and 56 GA patients did not differ in gender, race, age at symptom onset (30.3 years) or disease duration at the start of treatment (5.7 years). Patients with pretreatment SC relapses had increased odds of having on-treatment SC compared with non-SC relapses (OR 2.31, p = 0.013); the same tendency for localisation occurred with BC (OR 3.05, p = 0.013) and ON (OR 3.63, p = 0.011) relapses. Additionally, patients who relapsed on treatment had a higher SC (but not ON or BC) relapse risk when they were receiving IFNB compared with GA (OR 2.05, p = 0.041). independent of pretreatment relapse location. Conclusion: These results show a tendency for patients to have localised exacerbations, which could be mediated by genetic or immunological factors. In addition, and to be confirmed in subsequent studies, IFNB treatment may influence SC relapse risk.
ACCESSION #
34752546

 

Related Articles

  • Location of relapses in relapsingremitting multiple sclerosis. Woodward, Sue // British Journal of Neuroscience Nursing;Apr2009, Vol. 5 Issue 4, p186 

    The article presents a brief description of research seeking to determine if the initial event location predicted the location of subsequent relapses in those with relapsing-remitting multiple sclerosis (RRMS). Initial lesions presented in the spinal cord or optic nerve significantly increased...

  • T1 hypointensity of the spinal cord in multiple sclerosis. Losseff, N. A.; Wang, L.; Miller, D. H.; Thompson, A. J. // Journal of Neurology;Jun2001, Vol. 248 Issue 6, p517 

    It has recently been shown in multiple sclerosis (MS) that the volume of T1 hypointense lesions in the brain explains more of the variance in disability amongst patients than T2 lesion volume. T1 hypointense lesions may therefore represent areas of underlying pathology likely to be of functional...

  • Transcranial magnetic stimulation: Role in the evaluation of disability in multiple sclerosis. Sahota, Preeti; Prabhakar, Sudesh; Lal, Vivek; Khurana, Dheeraj; Das, Chandi R.; Singh, Parampreet // Neurology India;Jun2005, Vol. 53 Issue 2, p197 

    Background: In patients with multiple sclerosis (MS), transcranial magnetic stimulation (TMS) has shown significant prolongation of central motor conduction time (CMCT). Abnormal CMCT may reflect sub-clinical involvement of motor pathways and correlate with clinical motor disability. Objective:...

  • Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient. Bernal-Cano, F.; Joseph, J. T.; Koralnik, I. J. // Journal of NeuroVirology;Oct2007, Vol. 13 Issue 5, p474 

    Progressive multifocal leukoencephalopathy (PML) is a deadly demyelinating disease of the central nervous system, which occurs in immunosuppressed individuals. This disease is caused by a reactivation of the polyomavirus JC (JCV). Clinical presentation can be variable from patient to patient as...

  • Anti-aquaporin 4 antibody in selected Japanese multiple sclerosis patients with long spinal cord lesions. Tanaka, K.; Tani, T.; Tanaka, M.; Saida, T.; Idezuka, J.; Yamazaki, M.; Tsujita, M.; Nakada, T.; Sakimura, K.; Nishizawa, M. // Multiple Sclerosis (13524585);Aug2007, Vol. 13 Issue 7, p850 

    Multiple sclerosis (MS) in Asian populations is often characterized by the selective involvement of the optic nerve (ON) and spinal cord (SP) (OSMS) in contrast to classic MS (CMS), where frequent lesions are observed in the cerebrum, cerebellum or brainstem. In Western countries, inflammatory...

  • Predictors of Attack Severity and Duration in Multiple Sclerosis: A Prospective Study. Naldi, P.; Collimedaglia, L.; Vecchio, D.; Rosso, M. G.; Perla, F.; Stecco, A.; Monaco, F.; Leone, M. A. // Open Neurology Journal;2011, Vol. 5, p75 

    Objective: To evaluate predictors of severity and duration of early Multiple Sclerosis (MS) attacks. Methods: We analyzed 248 attacks in 95 patients in a prospective study. Severity: the difference between the EDSS score at the day of maximum worsening and the EDSS score before the onset of the...

  • Vestibular click-evoked myogenic potentials: sensitivity and factors determining abnormality in patients with multiple sclerosis. Patkó, T.; Simó, M.; Arányi, Z. // Multiple Sclerosis (13524585);Mar2007, Vol. 13 Issue 2, p193 

    Vestibular evoked myogenic potential (VEMP) assesses the sacculo-spinal pathway. The aim of our study was to examine sensitivity and factors determining abnormality of VEMP, indicative of brainstem dysfunction, in patients with multiple sclerosis (MS). Thirty healthy subjects and 30 MS patients...

  • Insight into Multiple Sclerosis. Wehman-Tubbs, Kelli; Yale, Steven H.; Rolak, Loren A. // Clinical Medicine & Research;Feb2005, Vol. 3 Issue 1, p41 

    Presents information on multiple sclerosis. Knowledge of the pathogenesis of multiple sclerosis; Definition of the most common presentation for patients with multiple sclerosis; Tests available to assist in the diagnosis of multiple sclerosis.

  • The Lesions of Multiple Sclerosis. Paty, Donald W.; Arnold, Douglas L. // New England Journal of Medicine;1/17/2002, Vol. 346 Issue 3, p199 

    Editorial. Discusses multiple sclerosis (MS). Reference to reports by Chang and colleagues and by Brex et al in this issue; How the findings are important to an understanding of the remyelination of lesions of MS and imply that transplantation of oligodendrocyte precursor cells will probably not...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics